Cell Therapy’s Got Talent Technology Showcase – A Call for Cell Therapy Manufacturing Technology Presentations
By Dr. Matthew Watson
in collaboration with:
In an effort to showcase the latest technologies driving the production of cell therapies, the Cell Therapy Group and Informa Life Sciences are proud to announce the introduction of the "Technology Showcase" session and award to be held in conjunction with Informa's Cell Therapy Manufacturing conference to be held 30 November to 1 December 2011 in Brussels Belgium.
Having held the same conference last year in London, Informa is committed to building on the success of last year's event by continuing to create a meaningful European forum for the issues related to the clinical and particularly commercial-scale production of cell-based therapies.
The Technology Showcase session, taking place on the main agenda, will feature 6 x 10 minute presentations from innovative companies developing cutting-edge technologies in the field of cell therapy manufacturing, and is particularly relevant to SME and academic groups with limited marketing resources.
All presentations will be reviewed by the Scientific Advisory Board with the winner announced at the end of the session. Exposure on BioProcess International's website is also included.
Technologies we'd like to promote include:
- Manufacturing systems including bioreactor technologies
- Cell harvest/collection technologies
- Cell storage/logistics technologies
- Clinical cell delivery and/or other point-of-care technologies
- Automation technologies
- Cell separation system
- Cell process devices
- Innovative reagents, scaffolds, matrices, and other “ancillary” tools
- Technologies to close currently open systems
- Suspension-based production systems
- Disposable technologies
How to apply:
To apply to present companies must submit an abstract (<300 words) to daniel.barry@informa.com and lbuckler@celltherapygroup.com outlining the product or service to be presented and why it is a critical technology related to cell therapy manufacturing.
The deadline for applications is SEPTEMBER 15 2011 - Priority given to early submissions
The cost of taking part in the Technology Showcase is £2,700 which includes the following benefits:
- 1 x 2-day conference pass (normal price £1,599)
- 10-minute podium presentation within main conference room
- 1 poster display in the Exhibition Hall
- Marketing - company logo displayed on website and event guide
- Exposure in BPI Magazine
Terms and conditions:
To be eligible the product or service to be presented must be:
- On the market for no less than 2 years or expected to be on the market no later than Q4 2012
- Appropriate for, applicable to, and compliant with clinical-grade manufacturing requirements (technologies only available for research use will not be considered)
Plus...
- The company must have no more than 15 employees
- The company has been running for no more than 5 years, and
- The company generates annual revenue of no more than $5m
For further information please contact: daniel.barry@informa.com or lbuckler@celltherapygroup.com
- 001 Stem cells for a Webby! [Last Updated On: April 28th, 2010] [Originally Added On: April 28th, 2010]
- 002 Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: April 30th, 2010] [Originally Added On: April 30th, 2010]
- 003 Google to Invest in Regenerative Medicine [Last Updated On: May 5th, 2010] [Originally Added On: May 5th, 2010]
- 004 Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: May 22nd, 2010] [Originally Added On: May 22nd, 2010]
- 005 The changing face of PR and why it matters to regenmed [Last Updated On: June 12th, 2010] [Originally Added On: June 12th, 2010]
- 006 FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 007 Careers in cell therapy & regenerative medicine [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 008 The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: January 15th, 2011] [Originally Added On: January 15th, 2011]
- 009 Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: February 12th, 2011] [Originally Added On: February 12th, 2011]
- 010 In vivo cell trafficking just took a leap forward [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- 011 Clinical trial costs [Last Updated On: July 31st, 2011] [Originally Added On: July 31st, 2011]
- 012 Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- 013 Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 014 Commercial-stage Cell Therapy Companies and Products [Last Updated On: September 18th, 2011] [Originally Added On: September 18th, 2011]
- 015 Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- 016 Commercializing Cell-based Regenerative Medicines [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- 017 Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: November 27th, 2011] [Originally Added On: November 27th, 2011]
- 018 Active phase III or II/III cell therapy trials [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 019 Recently approved cell therapy products [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 020 Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 021 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 022 Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? [Last Updated On: March 11th, 2012] [Originally Added On: March 11th, 2012]
- 023 Another > $100M month for companies in the cell therapy space [Last Updated On: May 6th, 2012] [Originally Added On: May 6th, 2012]
- 024 Cell-based Cancer Immunotherapies. Some metrics.. [Last Updated On: May 20th, 2012] [Originally Added On: May 20th, 2012]
- 025 Industry-sponsored cardiovascular cell therapies. Some metrics. [Last Updated On: May 27th, 2012] [Originally Added On: May 27th, 2012]
- 026 Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing [Last Updated On: June 17th, 2012] [Originally Added On: June 17th, 2012]
- 027 FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) [Last Updated On: July 29th, 2012] [Originally Added On: July 29th, 2012]
- 028 Is the cell therapy sector outperforming the major indices? [Last Updated On: August 12th, 2012] [Originally Added On: August 12th, 2012]
- 029 Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: September 2nd, 2012] [Originally Added On: September 2nd, 2012]
- 030 Two lessons I learned this week. [Last Updated On: September 16th, 2012] [Originally Added On: September 16th, 2012]
- 031 The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- 032 Anticipated short-term cell therapy industry clinical milestones [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- 033 Cell therapy portfolio outperforms major indices year-to-date [Last Updated On: October 14th, 2012] [Originally Added On: October 14th, 2012]
- 034 CIRM addresses some tough questions. Is it all just glass towers and basic research? [Last Updated On: October 21st, 2012] [Originally Added On: October 21st, 2012]
- 035 GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: November 4th, 2012] [Originally Added On: November 4th, 2012]
- 036 Cell Therapy Industry Group Welcomes its 4,000th member [Last Updated On: November 11th, 2012] [Originally Added On: November 11th, 2012]
- 037 Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. [Last Updated On: December 2nd, 2012] [Originally Added On: December 2nd, 2012]
- 038 A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments [Last Updated On: December 16th, 2012] [Originally Added On: December 16th, 2012]
- 039 The ROI on pant-wearing and other social media tips [Last Updated On: December 16th, 2012] [Originally Added On: December 16th, 2012]
- 040 The Accuracy of Adipose Stem Cell Doses [Last Updated On: December 23rd, 2012] [Originally Added On: December 23rd, 2012]
- 041 Cell Therapy Blog welcomes 2013 [Last Updated On: January 6th, 2013] [Originally Added On: January 6th, 2013]
- 042 2013 Annual Regenerative Medicine Industry Report [Last Updated On: April 21st, 2013] [Originally Added On: April 21st, 2013]
- 043 Commercialization of Regenerative Medicine: Learning from Spin-Outs [Last Updated On: April 28th, 2013] [Originally Added On: April 28th, 2013]
